Clinical Trials
8 trialsNCT00828308 2022-03-08
Neoadjuvant Weekly Ixabepilone for High Risk, Clinically Localized Prostate Cancer
Brown University
Phase 2 Completed
NCT01079793 2020-08-20
Radiation Therapy and Ixabepilone in Treating Patients With High-Risk Stage III Prostate Cancer After Surgery
University of Texas Southwestern Medical Center
Phase 1/2 Withdrawn
NCT00672009 2018-10-24
A Study of Ixabepilone Before Surgery for High-Risk Localized Prostate Cancer
Cedars-Sinai Medical Center
Phase 2 Terminated
NCT00331344 2017-10-31
Treating Patients With Metastatic Prostate Cancer Not Responding to Hormone and Chemotherapy
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00058084 2017-02-23
Ixabepilone Compared With Mitoxantrone and Prednisone in Treating Patients With Refractory Metastatic Prostate Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00087139 2014-05-09
Ixabepilone in Treating Patients With Metastatic Prostate Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00016393 2013-06-24
BMS-247550 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy
National Cancer Institute (NCI)
Phase 2 Completed
NCT00025194 2013-06-24
Ixabepilone With or Without Estramustine in Treating Patients With Progressive Prostate Cancer
National Cancer Institute (NCI)
Phase 1/2 Completed